(Q46127191)

19 December 2017

title

Fluconazole in the treatment of chronic pulmonary and nonmeningeal disseminated coccidioidomycosis. NIAID Mycoses Study Group (English)

1 reference

19 December 2017

1 reference

Catanzaro A

1

1 reference

19 December 2017

Galgiani JN

2

1 reference

19 December 2017

Levine BE

3

1 reference

19 December 2017

Sharkey-Mathis PK

4

1 reference

19 December 2017

Fierer J

5

1 reference

19 December 2017

Stevens DA

6

1 reference

19 December 2017

Chapman SW

7

1 reference

19 December 2017

Cloud G

8

1 reference

19 December 2017

language of work or name

English

0 references

publication date

1 March 1995

1 reference

19 December 2017

American Journal of Medicine

published in

1 reference

19 December 2017

volume

98

1 reference

19 December 2017

issue

3

1 reference

19 December 2017

page(s)

249-256

1 reference

19 December 2017

Amphotericin B in the treatment of coccidioidomycosis.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980371-4

Ketoconazole for treatment of chronic pulmonary coccidioidomycosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980371-4

Ketoconazole for Treatment of Disseminated Coccidioidomycosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980371-4

Ketoconazole therapy of progressive coccidioidomycosis. Comparison of 400- and 800-mg doses and observations at higher doses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980371-4

Ketoconazole treatment of nonprimary coccidioidomycosis. Evaluation of 60 patients during three years of study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980371-4

Experience with ketoconazole in three major manifestations of progressive coccidioidomycosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980371-4

Pharmacology and toxicity of high-dose ketoconazole

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980371-4

Oral azole drugs as systemic antifungal therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980371-4

Itraconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980371-4

Itraconazole treatment of coccidioidomycosis. NAIAD Mycoses Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980371-4

Fluconazole, a new antifungal agent

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980371-4

A Pan-American 5-year study of fluconazole therapy for deep mycoses in the immunocompetent host. Pan-American Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980371-4

Fluconazole in the treatment of persistent coccidioidomycosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980371-4

Treatment of coccidioidomycosis with ketoconazole: An evaluation utilizing a new scoring system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980371-4

Nonparametric Estimation from Incomplete Observations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980371-4

Hypercalcemia in disseminated coccidioidomycosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980371-4

Cellular immune response in coccidioidomycosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980371-4

10.1016/S0002-9343(99)80371-4

7 January 2021

Identifiers

DOI

1 reference

19 December 2017

1 reference

19 December 2017